Nonclinical Study Report Writing for Drug and Device Developers
Pubrica writes nonclinical study reports and CTD nonclinical summaries for drug and device developers. Our nonclinical writers prepare individual study reports, the CTD Module 2.4 nonclinical overview and the Module 2.6 written summaries. Pharmacology, pharmacokinetic and toxicology findings are reported accurately and then interpreted for the clinical stage, including what each finding implies for the first human dose.
- Findings translated to clinical consequence, with the exposure margin and the monitoring implication stated rather than left in a species table
- Module 2.4 written as a critical overview — an integrated assessment across the nonclinical programme rather than a longer version of 2.6
- Module 2.6 built by extraction where the underlying reports support it, which removes a round of reconciliation
- Consistent with the investigator’s brochure and the protocol, because the same toxicology has to justify the same monitoring in all three
- Written for your current clinical stage, under ICH M3(R2), which determines whether the package is sufficient
Nonclinical study reportsIncluded
Module 2.4 nonclinical overviewIncluded
Module 2.6 written summariesIncluded
Translation to clinical consequenceIncluded
Conducting the studiesYour laboratory or CRO
Study data → reported → summarised → interpreted → module
- Findings tied to exposure margins
- 2.4 written as an integrated assessment
- 2.6 traced to source reports
- Reconciled with the brochure
- Sufficiency assessed against M3(R2)
Deliverables
Four Core Elements of Every Nonclinical Package
Each package supports one compound at one clinical stage, and ICH M3(R2) sets what is sufficient at that stage.
Example from a toxicology summaryHepatocellular hypertrophy was observed in the 13-week rat study.Hepatocellular hypertrophy at exposures four times the proposed human dose, reversible within the four-week recovery period, and the basis for the liver monitoring schedule proposed in the protocol.
Example from Module 2.4The overview is the one place in the nonclinical file where the sponsor presents an argument rather than a report, and reviewers read it first. Writing it as a longer 2.6 loses that opportunity.
Example from a gap assessmentThe most common finding is a package that is adequate for a single ascending dose study but not for the multiple-dose study described in the protocol. Identified before submission, it is a scheduling decision; identified afterwards, it can lead to a clinical hold.
Example from a consistency checkIf the brochure describes a monitoring requirement that the nonclinical data do not support, or omits one that the data do support, an ethics committee is likely to ask about it.
The samples shown are illustrative and anonymised. Hover over a sample to replay it.
Compliance and Standards
Four Governing Standards and Guidelines for Nonclinical Study Reports
Where your agency has given advice on the programme, that advice takes precedence.
Nonclinical safety studies for clinical trials (and the S-series)
What nonclinical support is required at each stage of clinical development, and therefore whether the package is sufficient for the study you intend to run.
Good Laboratory Practice (OECD principles)
The conduct and reporting standard the pivotal studies are held to, and what a report has to record about compliance.
Common Technical Document (Modules 2.4, 2.6 and 4)
The nonclinical overview, the written and tabulated summaries, and the study reports themselves.
Quality management (cert. H3CR9TCU20251212INDQM10N)
How the document is drafted, reviewed, version-controlled and released.
Responsible Use of AI
Responsible Use of AI in Regulatory Writing
Regulatory reviewers trace each decision back to its evidence and to a responsible individual. For this reason, we treat source traceability as more important than drafting speed, and every statement in a regulatory document must be traceable to its source.
Why We Do Not Publish an AI Accuracy Figure
Accuracy figures for AI tools are usually reported by the companies that sell them.
Pubrica therefore does not quote a self-generated accuracy figure, because it would carry the same conflict of interest. Instead, we tell you which tool was used on your project, at which stage, and what a specialist changed afterwards.
Methodology
How We Write Your Nonclinical Study Reports
We assess sufficiency first, because there is little value in summarising a package that will not support the intended clinical stage.
Package review and sufficiency check
We assess the existing studies against ICH M3(R2) for the proposed clinical stage and identify gaps before writing begins.
Study reports
We write or review individual reports, tying each finding to exposure and reversibility rather than reporting it as an observation.
Module 2.6 summaries
We build the written and tabulated summaries from the study reports and trace every figure to its source.
Module 2.4 overview and reconciliation
We write the integrated assessment last, then reconcile it against the brochure and the protocol so that the same toxicology data justify the same clinical measures.
Our Experts
Our Regulatory Writing Team
A named team of regulatory specialists stays with your project from scoping to delivery. Your project coordinator introduces each team member by name before work begins.
Writes the document against the governing template and regulatory guidance, keeps every statement traceable to its source data, and maintains the version history and comment log through each review round.
Reviews the clinical and scientific content for accuracy and confirms that each conclusion is supported by the data. Each expert is matched to your therapeutic or device area.
Checks that statistical methods, tables and conclusions are consistent with the analysis plan, and reviews how the data are presented before the document reaches regulatory review.
Performs an independent check of the final document against source data, the template and the applicable regulatory checklist. Findings are logged and resolved before delivery.
Packages
Nonclinical Writing Packages
Pricing depends on the number of studies, the programme stage and whether reports already exist.
Study reports
Sponsors needing individual nonclinical reports written
Quoted per projectOn study count and complexity
Delivery By scope
- ✓Pharmacology, pharmacokinetic or toxicology reports
- ✓Findings tied to exposure margins and reversibility
- ✓GLP compliance statement handled correctly
- ✓Written for a regulatory and clinical reader
- ✓Two review cycles
Reports written with reuse in mind allow the Module 2.6 summaries to be largely extracted from them.
Deliverables Request a quoteModule 2.4 and 2.6
For sponsors assembling the nonclinical file
Quoted per projectOn programme size
Delivery By scope
- ✓Module 2.6 written and tabulated summaries
- ✓Module 2.4 nonclinical overview as an integrated assessment
- ✓Sufficiency assessed against ICH M3(R2)
- ✓Every figure traced to source
- ✓Reconciled with brochure and protocol
The sufficiency assessment is useful even if the writing is done elsewhere.
Deliverables Request a quoteSend us the study list and your target clinical stage, and we will tell you free of charge whether the package supports it under ICH M3(R2).
FAQs
Nonclinical Study Report FAQs
If your question is not answered here, ask an expert — no quote is required.
ICH M3(R2) sets what is needed at each clinical stage — single dose, repeat dose, duration, genotoxicity, reproductive toxicity and the rest — and sufficiency is assessed against the study you actually intend to run.
The most common gap we see is a package adequate for a single ascending dose study being used to support a multiple-dose protocol. Found early, it is a scheduling decision; found at submission, it can lead to a clinical hold.
2.6 is the factual summary — written summaries and tabulated summaries of the nonclinical studies. 2.4 is the integrated critical assessment that concludes on adequacy.
Writing 2.4 as a longer 2.6 misses the one place in the nonclinical file where the sponsor makes its argument, and reviewers read it before anything else.
No. Study conduct sits with your laboratory or your nonclinical CRO under GLP. We write and summarise what they produce.
Where the package has a gap, we describe the study that would close it and what it would need to show, but the study itself is conducted by your laboratory or CRO.
Yes, though that is a different framework. Biological evaluation under ISO 10993 sits with the device technical documentation rather than with a CTD nonclinical module.
The approach is the same, with findings tied to exposure and clinical consequence, but the structure and the reviewer differ.
Related Services
Related Regulatory Writing Services
Nonclinical data justify the first clinical dose and the monitoring that accompanies it.
1CLINICAL TRIAL DOCUMENTSmust be consistent with the nonclinical data
Investigator's brochureWhere the toxicology becomes guidance. Clinical study protocolWhere the monitoring is specified.2OTHER DOSSIER DOCUMENTSin the same submission
CTD module summariesModule 2.5 and 2.7, the clinical side. Regulatory writingDossiers, briefs and submissions.Request a Free ICH M3(R2) Sufficiency Check of Your Nonclinical Package
We will tell you free of charge whether your nonclinical package supports the intended clinical stage under ICH M3(R2). Assessing sufficiency early helps avoid delays later in the development programme.